RU2013108256A - Дисперсии цитрата разагилина - Google Patents

Дисперсии цитрата разагилина Download PDF

Info

Publication number
RU2013108256A
RU2013108256A RU2013108256/15A RU2013108256A RU2013108256A RU 2013108256 A RU2013108256 A RU 2013108256A RU 2013108256/15 A RU2013108256/15 A RU 2013108256/15A RU 2013108256 A RU2013108256 A RU 2013108256A RU 2013108256 A RU2013108256 A RU 2013108256A
Authority
RU
Russia
Prior art keywords
rasagiline
solid dispersion
solvent
pharmaceutical excipient
pharmaceutically acceptable
Prior art date
Application number
RU2013108256/15A
Other languages
English (en)
Russian (ru)
Inventor
Кит Лоример
Дэвид ЭНДЖЕРС
Original Assignee
Тева Фармасьютикал Индастриз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриз Лтд. filed Critical Тева Фармасьютикал Индастриз Лтд.
Publication of RU2013108256A publication Critical patent/RU2013108256A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2013108256/15A 2010-07-27 2011-07-27 Дисперсии цитрата разагилина RU2013108256A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40036910P 2010-07-27 2010-07-27
US61/400,369 2010-07-27
PCT/US2011/045569 WO2012015946A1 (en) 2010-07-27 2011-07-27 Dispersion of rasagiline citrate

Publications (1)

Publication Number Publication Date
RU2013108256A true RU2013108256A (ru) 2014-09-10

Family

ID=45530490

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013108256/15A RU2013108256A (ru) 2010-07-27 2011-07-27 Дисперсии цитрата разагилина

Country Status (7)

Country Link
US (2) US8691872B2 (enExample)
EP (1) EP2598136A4 (enExample)
JP (1) JP2013537530A (enExample)
AU (1) AU2011282716A1 (enExample)
CA (1) CA2806737A1 (enExample)
RU (1) RU2013108256A (enExample)
WO (1) WO2012015946A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2643235C (en) * 2006-02-21 2014-06-17 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
MX2008012781A (es) * 2006-04-03 2008-10-14 Teva Pharma Uso de rasagilina para el tratamiento de sindrome de piernas inquietas.
EA016820B1 (ru) * 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Кристаллическое твердое основание разагилина
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
AU2009204454B2 (en) * 2008-01-11 2015-02-05 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations, their preparation and use
JP2011524353A (ja) * 2008-06-10 2011-09-01 テバ ファーマシューティカル インダストリーズ リミティド ラサギリン軟ゼラチンカプセル
CA2767592A1 (en) 2009-07-09 2011-01-13 Ratiopharm Gmbh Salts of rasagiline and pharmaceutical preparations thereof
CA2777185A1 (en) * 2009-10-09 2011-04-14 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of progressive supranuclear palsy
EP2515891A4 (en) * 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
EP2603212A4 (en) 2010-07-27 2014-01-08 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF SMOKING DISORDER
BR112014008552A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-metil-propargilaminoindano
AU2012323349A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-formyl-propargyl-aminoindan
TW201412304A (zh) 2012-08-17 2014-04-01 Teva Pharma 瑞沙吉林之非經腸調配物
CN110840845B (zh) 2018-11-16 2022-10-21 江苏恒瑞医药股份有限公司 一种包含parp抑制剂的药物组合物
EP4035654A1 (en) 2021-01-30 2022-08-03 Intas Pharmaceuticals Limited An orodispersible pharmaceutical solid dosage form of rasagiline
WO2022162612A1 (en) 2021-01-30 2022-08-04 Intas Pharmaceuticals Ltd. An orodispersible pharmaceutical solid dosage form of rasagiline

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL112819A (en) 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
EP0966435B1 (en) 1996-12-18 2005-04-06 Teva Pharmaceutical Industries, Ltd. Aminoindan derivatives
EP1567152B1 (en) 2002-11-15 2013-08-14 Teva Pharmaceutical Industries Limited Use of rasagiline with riluzole to treat amyotrophic lateral sclerosis
EP1694305B1 (en) * 2003-12-01 2019-10-16 Recordati Ireland Limited Pharmaceutical compositions comprising lercanidipine
AU2005269416B2 (en) 2004-07-26 2011-07-28 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
ES2371883T3 (es) 2004-11-24 2012-01-11 Teva Pharmaceutical Industries Ltd. Composiciones de rasagilina de disgregación oral.
KR20130129300A (ko) 2005-02-23 2013-11-27 테바 파마슈티컬 인더스트리즈 리미티드 함량 균일성이 개선된 라사길린 제형
CA2630037C (en) 2005-11-17 2015-03-31 Teva Pharmaceutical Industries Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
CA2643235C (en) 2006-02-21 2014-06-17 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
CN101032474B (zh) 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
MX2008012781A (es) 2006-04-03 2008-10-14 Teva Pharma Uso de rasagilina para el tratamiento de sindrome de piernas inquietas.
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
EA016820B1 (ru) 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Кристаллическое твердое основание разагилина
NZ577623A (en) 2006-12-14 2011-05-27 Teva Pharma Tannate salt of rasagiline
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
AU2008296908B2 (en) 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
AU2009204454B2 (en) 2008-01-11 2015-02-05 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations, their preparation and use
JP2011524353A (ja) 2008-06-10 2011-09-01 テバ ファーマシューティカル インダストリーズ リミティド ラサギリン軟ゼラチンカプセル
MX2010013766A (es) * 2008-06-13 2011-03-15 Teva Pharmaceutical Ind Ltd Star Rasagilina para modificacion de enfermedad de parkinson.
AU2009260728B2 (en) 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
US8334409B2 (en) 2008-06-19 2012-12-18 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
EP2218444A3 (en) * 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US20100189788A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
CA2767592A1 (en) 2009-07-09 2011-01-13 Ratiopharm Gmbh Salts of rasagiline and pharmaceutical preparations thereof
CA2777185A1 (en) 2009-10-09 2011-04-14 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of progressive supranuclear palsy
EP2515891A4 (en) 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan
EP2603212A4 (en) 2010-07-27 2014-01-08 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF SMOKING DISORDER
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
PH12013500821A1 (en) 2010-10-26 2019-07-03 Teva Pharma Deuterium enriched rasagiline
BR112014008552A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-metil-propargilaminoindano
AU2012323349A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-formyl-propargyl-aminoindan
EA201490756A1 (ru) 2011-10-10 2014-09-30 Тева Фармасьютикал Индастриз, Лтд. Разагилина цитрамид

Also Published As

Publication number Publication date
CA2806737A1 (en) 2012-02-02
WO2012015946A8 (en) 2013-01-31
US20120059058A1 (en) 2012-03-08
US8691872B2 (en) 2014-04-08
AU2011282716A1 (en) 2013-03-14
WO2012015946A1 (en) 2012-02-02
EP2598136A4 (en) 2015-03-25
EP2598136A1 (en) 2013-06-05
JP2013537530A (ja) 2013-10-03
US20140194510A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
RU2013108256A (ru) Дисперсии цитрата разагилина
JP2013537530A5 (enExample)
JP2009530415A5 (enExample)
WO2016038532A1 (en) Amorphous treprostinil diethanolamine
JP2012236837A5 (enExample)
CO6470892A2 (es) Composiciones farmacéuticas sólidas y proceso para su producción
JP2009530416A5 (enExample)
HRP20221355T1 (hr) Liofilizirani pripravak citotoksičnih dipeptida
NO321523B1 (no) Preparat omfattende et nitroksyderivat, farmasoytisk formulering inneholdende dette og fremgangsmate for fremstilling av preparatet.
KR101895962B1 (ko) 알리사르탄 이소프록실 고체 분산체 및 이를 포함하는 약제학적 조성물
JP2010536837A5 (enExample)
RU2009137911A (ru) Порошки для создания жирной лекарственной формы
KR20160004483A (ko) 리바록사반을 포함하는 경구 투여용 약학 조성물 및 이의 제조방법
WO2017054741A1 (zh) 提高索拉非尼生物利用度的制剂
JP2014519475A (ja) 非晶質アシアト酸トロメタミン塩及びその調製方法
JP2017505313A5 (enExample)
JP7733160B2 (ja) カンナビジオール懸濁液を含有する可溶性マイクロニードル及びその調製方法
CN106138019A (zh) Gpr35受体激动剂及其应用
CN108186597A (zh) 一种鲁比前列酮固体分散体及其制备方法
CN102871994B (zh) 氟比洛芬对乙酰氨基酚酯环糊精包合物及其制备方法
CN102977039B (zh) 6-氟-3-羟基-2-吡嗪甲酰胺α晶型及其制备方法
CN111249226A (zh) 一种七叶皂苷可注射水凝胶及其制备方法和应用
CN102512392B (zh) 盐酸马尼地平固体分散体及制剂及其制备方法
CN106619503B (zh) 一种大黄酸酰胺类衍生物纳米混悬剂及其制备方法和应用
CN112972380B (zh) 一种多功能新型给药系统制剂的制备方法及应用

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20160122